Now that the first study sites have been initiated, we can start collecting clinical data. Data on the use of cangrelor in high-risk patients with acute myocardial infarction and PCI who have experienced CPR, cardiogenic shock or received mechanical or non-invasive ventilation will be collected from pre-existing clinical documentation and systematically analyzed. The register trial has also been extended to include clinical trial sites in Austria in order to be able to generate a significant number of patient outcomes. The goal is to generate clinical data from approximately 450 consecutive patients within the next six months.
First patient included in the CRUZ-SENIOR STUDY.Read more
Another important milestone has been achieved, allowing the Institute for Myocardial Infarction Research to generate new data to understand the efficacy and safety of cangrelor in high-risk patients.Read more
Day-to-day research results on the COVID-19 situation in hospitals, based on our own COVID-19 registry.Read more